Tarsus Pharmaceuticals, Inc. cash flow to debt ratio of -13.30% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Tarsus Pharmaceuticals, Inc.'s free cash flow has increased -73.63% from $-84.59M last year to $-22.31M, signaling increasing performance

Tarsus Pharmaceuticals, Inc.'s debt to equity ratio is 0.26, which means that the company's assets are healthy financed, signaling financial stability.

Tarsus Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.32 last year to 0.26 today, signaling strengthened financials

Tarsus Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Tarsus Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Tarsus Pharmaceuticals, Inc.'s profit margin has increased (-87.86%) in the last year from -63.16% to -7.67%, signaling increasing performance

Tarsus Pharmaceuticals, Inc.'s short-term assets of $522.78M exceed its short-term liabilities of $135.69M

Tarsus Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tarsus Pharmaceuticals, Inc.'s return on equity of -13.53%, is lower than 15.00%, indicating bad performance

Tarsus Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tarsus Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Tarsus Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Tarsus Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Tarsus Pharmaceuticals, Inc.'s yearly earnings has increased -42.52% since last year from $-115.55M to $-66.42M, signaling increasing performance

Tarsus Pharmaceuticals, Inc.'s yearly revenue has increased 146.71% since last year from $182.95M to $451.36M, signaling increasing performance

ROIC -11.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Tarsus Pharmaceuticals, Inc.'s 3-year revenue CAGR of 159.54% is positive, indicating growing revenue over the past 3 years

Tarsus Pharmaceuticals, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Tarsus Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Tarsus Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Tarsus Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tarsus Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Tarsus Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tarsus Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Tarsus Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tarsus Pharmaceuticals, Inc. has a price-to-book ratio of 8.48x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Tarsus Pharmaceuticals, Inc. has a price-to-sales ratio of 4.85x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue